Lava Therapeutics Nv logo

Lava Therapeutics Nv Share Price (NASDAQ: LVTX)

$1.57

0.02

(1.29%)

Last updated on

Check the interactive Lava Therapeutics Nv Stock chart to analyse performance

Lava Therapeutics Nv stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$1.54
    Today's High:$1.57

    Day's Volatility :1.91%

  • 52 Weeks Low:$0.85
    52 Weeks High:$2.09

    52 Weeks Volatility :59.38%

Lava Therapeutics Nv Stock Returns

PeriodLava Therapeutics NvSector (Health Care)Index (Russel 2000)
3 Months
21.71%
3.6%
0.0%
6 Months
23.62%
-7.7%
0.0%
1 Year
0.0%
-12.6%
0.0%
3 Years
-35.12%
9.5%
-4.7%

Lava Therapeutics Nv Key Stats

Check Lava Therapeutics Nv key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.55
Open
$1.54
Today's High
$1.57
Today's Low
$1.54
Market Capitalization
$40.8M
Today's Volume
$161.7K
52 Week High
$2.093
52 Week Low
$0.8502
Revenue TTM
$5.0M
EBITDA
$-25.7M
Earnings Per Share (EPS)
$-1.06
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-90.19%

Stock Returns calculator for Lava Therapeutics Nv Stock including INR - Dollar returns

The Lava Therapeutics Nv stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Lava Therapeutics Nv investment value today

Current value as on today

₹94,998

Returns

₹5,002

(-5%)

Returns from Lava Therapeutics Nv Stock

₹10,286 (-10.29%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Lava Therapeutics Nv Stock

0%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Lava Therapeutics Nv Stock from India on INDmoney has increased by 0% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Lava Therapeutics Nv

  • Name

    Holdings %

  • Redmile Group, LLC

    7.89%

  • BML Capital Management LLC

    7.49%

  • Sanofi

    7.30%

  • Merck & Co Inc

    4.37%

  • Bruce & Co Inc

    1.98%

  • Pathway Financial Advisors LLC

    0.39%

Analyst Recommendation on Lava Therapeutics Nv Stock

Rating
Trend

Buy

    90%Buy

    9%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Lava Therapeutics Nv(by analysts ranked 0 to 5 stars)

Lava Therapeutics Nv Share Price Target

What analysts predicted

Downside of 12.06%

Target:

$1.38

Current:

$1.57

Lava Therapeutics Nv share price target is $1.38, a slight Downside of 12.06% compared to current price of $1.57 as per analysts' prediction.

Lava Therapeutics Nv Stock Insights

  • Price Movement

    In the last 7 days, LVTX stock has moved up by 2.6%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 227.99K → 4.99M (in $), with an average increase of 95.4% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -3.47M → -8.63M (in $), with an average decrease of 148.3% per quarter
  • LVTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 80.2%
  • LVTX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 151.5%
  • Price to Sales

    ForLVTX every $1 of sales, investors are willing to pay $8.4, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Lava Therapeutics Nv Technicals Summary

Sell

Neutral

Buy

Lava Therapeutics Nv is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Lava Therapeutics Nv Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Lava Therapeutics Nv logo
3.29%
23.62%
0.0%
-35.12%
-89.02%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Lava Therapeutics Nv

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. The company has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is based in Utrecht, the Netherlands.
Organization
Lava Therapeutics Nv
Employees
34
CEO
Mr. Stephen Allen Hurly M.B.A., M.Sc.
Industry
Services

Key Management of Lava Therapeutics Nv

NameTitle
Mr. Stephen Allen Hurly M.B.A., M.Sc.
CEO, President & Executive Director
Mr. Fred M. Powell CPA
Chief Financial Officer
Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.
Chief Medical Officer
Ms. Oxana Polyakova Ph.D.
Chief Scientific Officer
Ms. Amy Garabedian J.D.
General Counsel & Corporate Secretary
Dr. Hans van der Vliet M.D., Ph.D.
Head of Innovation
Dr. Ton Adang Ph.D.
Chief Development Officer

Important FAQs about investing in LVTX Stock from India :

What is Lava Therapeutics Nv share price today?

Lava Therapeutics Nv share price today is $1.57 as on at the close of the market. Lava Therapeutics Nv share today touched a day high of $1.57 and a low of $1.54.

What is the 52 week high and 52 week low for Lava Therapeutics Nv share?

Lava Therapeutics Nv share touched a 52 week high of $2.09 and a 52 week low of $0.85. Lava Therapeutics Nv stock price today i.e. is closed at $1.57, lower by 24.99% versus the 52 week high.

How to invest in Lava Therapeutics Nv Stock (LVTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lava Therapeutics Nv on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lava Therapeutics Nv Shares that will get you 0.9554 shares as per Lava Therapeutics Nv share price of $1.57 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Lava Therapeutics Nv Stock (LVTX) from India?

Indian investors can start investing in Lava Therapeutics Nv (LVTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Lava Therapeutics Nv stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Lava Therapeutics Nv share’s latest price of $1.57 as on August 30, 2025 at 1:29 am IST, you will get 6.3694 shares of Lava Therapeutics Nv. Learn more about fractional shares .

What are the returns that Lava Therapeutics Nv has given to Indian investors in the last 5 years?

Lava Therapeutics Nv stock has given -89.02% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?